Rei Okada

Dr. Rei Okada

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
YYYu Yoshino
Yu Yoshino
KFKimihiko Funahashi
Kimihiko Funahashi
RORei Okada
Rei Okada
YMYasuyuki Miura
Yasuyuki Miura
TSTakayuki Suzuki
Takayuki Suzuki
HKHironori Kaneko
Hironori Kaneko
Fournier’s gangrene in the setting of rectal cancer is rare. Treatment for Fournier’s gangrene associated with rectal cancer is more complex than other cases of Fournier’s gangrene. We report on a patient with severe Fournier’s gangrene in the setting of locally advanced rectal cancer who was treated with a combined modality therapy. A 65-year-old man presented with general fatigue and anal pain. The medical and surgical histories were unremarkable. A black spot on the perineal skin surrounded by erythema was found on physical examination, suspicious for Fournier’s gangrene. Computed tomography scan showed a rectal tumor invading into the bladder (clinically T4bN2M0) and abscess formation with emphysema around the rectum. He was thus diagnosed with locally advanced rectal cancer and Fournier’s gangrene with a severity index score of 12 points. We created a diverting loop colostomy of the transverse colon and performed extensive debridement of the perineum and perianal area. Fifty days later, the patient underwent radical total pelvic exenteration with sacrectomy. In addition, reconstruction of the soft tissue defect was performed using the rectus muscle, the gluteus maximus muscle, and the femoral muscle. Histopathological findings of the specimen were as follows: the tumor was a moderately adenocarcinoma with invasion to the bladder and the prostate (T4b), metastases to four resected lymph nodes (N2), and lymphovascular invasion. There were no major postoperative complications, and the patient was discharged 108 days postoperatively. We report a rare case of locally invasive rectal cancer associated with Fournier’s gangrene. This case highlights a usual cause of Fournier’s gangrene. Physicians should be cognizant not only of the more common condition but also of the rare presentations including those associated with rectal cancer.

25 March 2020 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
IHIsamu Hoshino
Isamu Hoshino
YNYoshihiro Nabeya
Yoshihiro Nabeya
NTNobuhiro Takiguchi
Nobuhiro Takiguchi
HGHisashi Gunji
Hisashi Gunji
FIFumitaka Ishige
Fumitaka Ishige
HSHIDEAKI Shimada
HIDEAKI Shimada
Background and Aim: We evaluated the clinicopathological and prognostic significance of serum p53 (s‐p53‐Abs) and serum NY‐ESO‐1 autoantibodies (s‐NY‐ESO‐1‐Abs) in esophageal squamous cell carcinoma (ESCC), gastric cancer and hepatocellular carcinoma (HCC).Patients and Methods: A total of 377 patients, 85 patients with ESCC, 248 patients with gastric cancer, and 44 patients with HCC were enrolled to measure s‐p53‐Abs and s‐NY‐ESO‐1‐Abs titers by the enzyme‐linked immunosorbent assay before treatment. The clinicopathological significance and prognostic impact of the presence of autoantibodies were evaluated. Expression data based on the Cancer Genome Atlas and the prognostic impact of gene expression was also examined for discussion.Results: The positive rates of s‐p53‐Abs were 32.9% in ESCC, 15% in gastric cancer, and 4.5% in HCC. The positive rates of s‐NY‐ESO‐1‐Abs were 29.4% in ESCC, 9.7% in gastric cancer, and 13.6% in HCC. The presence of s‐p53‐Abs was not associated with tumor progression in these three cancer types. On the other hand, the presence of s‐NY‐ESO‐1‐Abs was significantly associated with tumor progression in ESCC and gastric cancer. The presence of s‐p53‐Abs and/or s‐NY‐ESO‐1‐Abs was significantly associated with poor prognosis in gastric cancer but not in ESCC nor HCC.Conclusions: The presence of s‐p53‐Abs and/or s‐NY‐ESO‐1‐Abs was associated with tumor progression in ESCC and gastric cancer. These autoantibodies might have poor prognostic impacts on gastric cancer (UMIN000014530).

23 June 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
RORei Okada
Rei Okada
YOYuichiro Otsuka
Yuichiro Otsuka
TWTaiga Wakabayashi
Taiga Wakabayashi
MSMasahiro Shinoda
Masahiro Shinoda
TATakeshi Aoki
Takeshi Aoki
HSHIDEAKI Shimada
HIDEAKI Shimada

1 February 2015 in International Surgery
Verified
Journal Article
Open access
KKKazuhiko Kitaguchi
Kazuhiko Kitaguchi
YKYuichiro Kato
Yuichiro Kato
MKMotohiro Kojima
Motohiro Kojima
SOSatoshi Okubo
Satoshi Okubo
DTDaigoro Takahashi
Daigoro Takahashi
MKMasaru Konishi
Masaru Konishi
The patient was a 61-year-old male who was referred to our hospital after dilatation of the main pancreatic duct was detected by screening ultrasonography. Computed tomography revealed a protruding lesion measuring 15 mm in diameter within the main pancreatic duct in the head of the pancreas, and magnetic resonance cholangiopancreatography revealed interruption of the duct at the tumor site. We performed pancreaticoduodenectomy under a suspected diagnosis of invasive ductal carcinoma. Gross examination of the resected specimen showed that the tumor invaginated into the main pancreatic duct, and no mucin was found. Histological examination revealed proliferation of high-grade dysplastic cells in a tubulopapillary growth pattern. Immunohistochemically, cytokeratin 7 expression was detected, but not trypsin expression. Based on these morphological features, we diagnosed the tumor as intraductal tubulopapillary neoplasm (ITPN). We report the case with bibliographic consideration, together with a review of intraductal neoplasms of the pancreas encountered at our institution.

11 October 2023 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
TMTetsuya Maeda
Tetsuya Maeda
YOYuichiro Otsuka
Yuichiro Otsuka
RORei Okada
Rei Okada
YIYuko Ito
Yuko Ito
YMYu Matsumoto
Yu Matsumoto
KFKimihiko Funahashi
Kimihiko Funahashi

29 November 2023 in Research Square
Verified
Preprint
Open access
PDF file
RORei Okada
Rei Okada
YOYuichiro Otsuka
Yuichiro Otsuka
YKYoji Kajiwara
Yoji Kajiwara
TMTetsuya Maeda
Tetsuya Maeda
JIJun Ishii
Jun Ishii
HSHIDEAKI Shimada
HIDEAKI Shimada
BackgroundMidkine (MK) is a soluble cytokine, and its serum levels strongly correspond with protein expression levels in tumors. This study aimed to clarify the clinicopathological and prognostic significance of serum MK (s-MK) in patients with hepatocellular carcinoma (HCC).MethodsSerum samples were obtained before surgery from 123 patients with HCC who underwent surgery between 2012 and 2020. Based on the receiver operating characteristics curve, the best cutoff value for s-MK in differentiating HCC from healthy cases was 426 pg/mL. Patients’ clinicopathological variables and overall survival were compared between the s-MK-positive group and the s-MK-negative group.ResultsThe sensitivity, specificity, and accuracy of s-MK were 82.1%, 97.4%, and 88.0%, respectively. An s-MK-positive status was significantly associated with the number of tumors (≥ 2). The positivity rate of s-MK was significantly higher than that of α-fetoprotein and protein induced by vitamin K absence-II. In total, only 28% of the patients were positive for s-MK. The s-MK positive group showed significantly worse overall survival than the s-MK negative group. The multivariate analysis revealed that an s-MK-positive status was independently associated with poor prognosis.Conclusions-MK was useful in detecting early HCC. A s-MK-positive status was associated with the number of tumors and was an independent prognostic risk factor.